COMPANY

Tectonic Therapeutic

HQ: Watertown, MA source · tectonictx.com ↗ · New England

Location: Watertown, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction

Timeline

Feb 3, 2025 Raise Private placement: $185M (total, as published), announced Feb 3, 2025. Source: SEC filing. source ↗
Sep 4, 2024 Trial start Phase 2: A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) source ↗

Nov 24, 2026 (ESTIMATED) · Phase 2 · A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) · NCT06616974

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $185.0M. Last 2 years.

Feb 3, 2025 Private placement: $185M (total, as published), announced Feb 3, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06616974	A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)	Phase 2	Active, not recruiting	Sep 4, 2024	Nov 24, 2026 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

2025-02-14 Raise Private raise (SEC Form D): $185.0M sold; issuer “Tectonic Therapeutic, Inc.”. Verified from the SEC filing. SEC filing ↗